At 5.3% CAGR, the Europe Respiratory Inhalers Market is projected to be worth US$ 10,470.53 million by 2028, says The Business Market Insights    

According to the Business Market Insights’ research, the Europe respiratory inhalers market was valued at US$ 7,674.02 million in 2022 and is expected to reach US$ 10,470.53 million by 2028, registering a CAGR of 5.3% from 2022 to 2028. Rising cases of respiratory disorders and growing adoption of generic inhalers are the critical factors attributed to the Europe respiratory inhalers market expansion.                    

Inhaled medicines involving a wide range of inhalation devices are the mainstay of pharmacological treatment for asthma and COPD. Patients suffering from asthma and COPD often need one or more inhalers daily to keep their airways healthy. Therefore, healthcare professionals are concerned about switching between medications as it can negatively impact disease control through low adherence and misuse of aerosol delivery device types. With increasing pressure on healthcare budgets and the simultaneous expiration of patents on established inhalation treatments, several generic replacement products are being manufactured and supplied across the region. Several inhalants that are used to treat asthma include generic formulations, such as albuterol, levalbuterol, ipratropium, budesonide, and fluticasone/salmeterol. The generic inhalers are bioequivalent to the branded versions and have the same effect on the body. The number of generic asthma inhalers continues to increase as patents expire. As more generic drugs are entering the market, increased competition is expected, which, in turn, leads to reduced costs of drugs. Cost reductions can also result from the launch of an “approved generic drug.” Thus, the growing adoption of generic inhalers and asthma medications is improving medication adherence, thereby driving the Europe respiratory inhalers market.

On the contrary, lack of early diagnosis and high cost of inhalers hurdles the growth of Europe respiratory inhalers market.   

Based on product type, the Europe respiratory inhalers market is segmented into nebulizers, metered dose inhalers (MDI), and dry powder inhalers. The dry powder inhalers segment held 44.0% market share in 2022, amassing US$ 3,376.70 million. It is projected to garner US$ 4,532.20 million by 2028 to expand at 5.0% CAGR during 2022–2028.   

Based on technology, the Europe respiratory inhalers market is bifurcated into manually operated inhalers and digitally operated inhalers. The manually operated inhalers segment held 71.0% market share in 2022, amassing US$ 5,451.27 million. It is projected to garner US$ 7,559.63 million by 2028 to expand at 5.6% CAGR during 2022–2028.    

Based on disease indication, the Europe respiratory inhalers market is segmented into asthma, COPD, pulmonary arterial hypertension, and others.  The asthma segment held 35.0% market share in 2022, amassing US$ 2,684.44 million. It is projected to garner US$ 3,791.03 million by 2028 to expand at 5.9% CAGR during 2022–2028.   

Based on country, the Europe respiratory inhalers market has been categorized into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.9% market share in 2022. It was assessed at US$ 2,290.70 million in 2022 and is likely to hit US$ 3,266.81 million by 2028, exhibiting a CAGR of 6.1% during the forecast period.        

Key players dominating the Europe respiratory inhalers market are AstraZeneca Plc; Beximco Pharmaceuticals Ltd.; Boehringer Ingelheim International GmbH; Cipla Ltd; GSK Plc; Koninklijke Philips NV; OMRON Corp; OPKO Health, Inc; PARI Respiratory Equipment, Inc.; and Teva Pharmaceutical Industries Ltd among others.         

• In Feb 2022, AstraZeneca partnership with Honeywell to develop next-generation respiratory inhalers. AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines.  

• In Feb 2022, Beximco Pharmaceuticals Launched Fixonase Nasal Spray. Fixonase Nasal Spray is the preparation of Fluticasone Furoate (27.5 g) indicated to treat symptoms of seasonal and perennial allergic rhinitis in patients above 2 years of age including stuffy, runny, or itchy nose, sneezing and watery, itchy, or red eyes.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com